MITSU™ POLYGLACTIN 910 SUTURES

Polyglactin 910 Suture

MITSUTM is a mid-term absorbable braided and coated synthetic suture made of poly (glycolide-co-l-lactide) (90/10). MITSUTM degrades by hydrolysis and assures predictable and reliable absorption.

Absorbable Poly(glycolide/L-Lactide) Surgical Suture

MITSUTM  braided coated synthetic absorbable sterile Poly(glycolide/L-Lactide) that is Polyglactin 910 Surgical Suture. It is composed of a copolymer made 90% Glycolide and 10% L-Lactide. MITSUTM sutures coated with mixture containing equal parts of copolymer of Glycolide, Lactide and Clacium stearate. The molecular formula of copolymer is (C2H2 O2)m (C3H4O2)n and (C36H70O4Ca).

Poly(glycolide/L-Lactide) polymer and Poly(glycolide/L-Lactide) with calcium stearate exhibit non-pyrogenic. MITSUTM sutures are available in undyed and dyed (D and C violet No. 2) form.

Available in a broad range of suture sizes and lengths, MITSUTM comes with standard stainless steel needles of varied types and sizes. MITSUTM complies with the “Absorbable Surgical Suture” requirements as per the United States Pharmacopeia (USP) and “Sterile Synthetic Absorbable braided strands” requirements as per the European Pharmacopeia (EP).

MITSU (Polyglactin 910 suture) can be described as The Power Of Three

  • Best-in-class raw material ensuring reliability
  • Sharper needles for easy and effortless penetration
  • Consistent performance at every pass due to high needle-thread integrity

MITSU Polyglactin 910 Sutures – Specifications, Features & Applications

Product Specifications:

Composition: Poly(glycolide/L-Lactide) i.e. Polyglactin 910

Structure: Multifilment, Braided

Colour: Dyed and Undyed

Sizes: Dyed: USP 8/0 - USP 2 | Undyed: USP 6/0 - USP 2

Suture Lenghts (cm): 35- 180

Needle Dimensions and Profiles: A variety ranging from 9 mm to 60 mm

Procedure-wise applications

  • Gastrointestinal procedures
  • Gynaecology & Obstetric procedures
  • Ophthalmic procedures 
  • Orthopaedic procedures
  • Urology procedures 
  • Skin closure (intracutaneous, subcutaneous)
  • Ligatures 

Polyglactin 910 Suture- Performance

MITSUTM  Polyglactin 910 suture leads to in growth of fibrous connective tissue due to minmal initial inflammatory tissue reaction. MITSU gradually loses tensile strength and is finally absorbed by hydrolytic process. During hydrolysis, the copolymer degrades to gylcolic and lactic acids which are then absorbed and metabolized in the body. Significant tensile strength i.e. 75% of the original is retained until initial 14 days, 40%-50% of the original is retained until 21 days (6-0 and larger) & (7-0 and smaller) and 24% of the original is retained until initial 28 days (6-0 and larger). There is a subsequent loss between four to five weeks post implantation. Complete absorption of MITSU suture usually takes place between 56 to 75 days.

Sterility:

MITSUTM  Polyglactin 910 sutures are sterilized by ethylene oxide (EtO). Do not re-sterilize, if re-sterilize, product may degrade and not perform as intended. Do not use if package is opened or damaged. Discard opened remaining unused sutures.

Contradictions:

Being absorbable, MITSU suture is not recommended where extended approximation of tissues under stress is required.

Storage:

Recommended storage conditions for MITSUTM Polypropylene sutures is between 15OC and 30OC, away from moisture and direct heat. Do not use after expiry date

 

  • RETAINS 75% KNOT TENSILE STRENGTH FOR UP TO 14 DAYS
  • RETAINS 50% KNOT TENSILE STRENGTH FOR UP TO 21 DAYS
  • COMPLETE MASS ABSORPTION BETWEEN 56 TO 70 DAYS

Benefits

MITSU

Indication of POLYGLACTIC 910 SUTURE

Intended for use in general soft tissue approximation and/or ligation

Peripheral nerve anastomosis, plastic and reconstructive procedures, microsurgery procedures, ophthalmic procedures and ligatures.

*Selection of surgical suture for implantation depends on patient condition, surgical experience, surgical technique and wound size

Clinical Data

STUDY NAME TYPE OF STUDY TOTAL PATIENTS STATUS LINK
MITSU Polyglactin 910 Suture Randomized controlled trial 122 Completed Know more
Enquire
Now